Zheng Quan Ri Bao Wang·2025-08-13 23:12Core Insights - The strategic cooperation agreement between China National Pharmaceutical Group (Sinopharm) and Gilead Sciences aims to enhance the accessibility of innovative antiviral drugs for chronic hepatitis B patients in China [1][2] - Approximately 86 million hepatitis B virus carriers exist in China, accounting for about one-third of the global infected population [1] - The new antiviral drug, Vemlidy (TAF), was launched in China in 2018 and has been included in the national medical insurance directory, making it more affordable for patients [2] Group 1 - The partnership will leverage Sinopharm's extensive network and marketing capabilities to improve the availability of Vemlidy in grassroots markets [1] - Chronic hepatitis B poses significant health risks, including liver cirrhosis and liver cancer, but advancements in antiviral medications have provided safer treatment options with low resistance rates [1] - Gilead Sciences has introduced eight global innovative drugs in China since 2017, focusing on improving drug accessibility through insurance and collaborations [2] Group 2 - Sinopharm's president emphasized the importance of brand, channel, and network advantages in increasing the medical coverage of Vemlidy for more hepatitis B patients [2] - The collaboration marks a new chapter in the ongoing partnership between Sinopharm and Gilead Sciences, which has previously involved a series of import agency collaborations [2]